What Are Wall Street Analysts’ Target Price for Moderna Stock? Are Wall Street analysts favoring Moderna’s stock? Barchart · Nov 10, 2025
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of $2.02, a turnaround from an income of 3 cents a year ago. Benzinga · Nov 6, 2025
Moderna Q3 2025 Earnings Call Transcript Moderna, Inc (NASDAQ:MRNA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below. MRNA is building positive momentum. Watch the momentum here This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visithttps://www.benzinga.com/apis/for a consultation. Operator… Benzinga · Nov 6, 2025
Pfizer COVID-19 vaccine sales drop 25% after confusing government guidance on the shot Previously, fall is when Americans would typically receive their vaccines The Independent UK · Nov 4, 2025
One molecule could usher revolutionary medicines for cancer, diabetes and genetic disease — but the US is turning its back on it The U.S. government is divesting from mRNA vaccines, but will other uses of the technology be spared? In a time of uncertainty, scientists worry that revolutionary treatments for cancer, immune dysfunction and genetic disease may be left on the lab bench. LiveScience · Oct 31, 2025
Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV. Benzinga · Oct 23, 2025
Moderna Earnings Preview: What to Expect Moderna is expected to announce its third-quarter results next month, and analysts expect a significant loss per share. Barchart · Oct 23, 2025
Moderna Stock Is at a Crossroads. Is the Path Ahead One of Profit or Pain for MRNA? Moderna’s story is far from over, but it needs patience and successful execution. Barchart · Oct 21, 2025
Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients Moderna Inc. (NASDAQ:MRNA) announced on Sunday that its clinical, safety, and translational data from its Phase 1/2 study evaluating mRNA-4359 in combination with pembrolizumab in patients with checkpoint inhibitor-resistant/refractory (CPI-R/R) melanoma will be presented at the 2025 European Society for Medical Oncology Congress. Benzinga · Oct 13, 2025
What do Musk, Microsoft’s CEO and the head of Zoom all have in common? The H-1B visa that is now in Trump’s crosshairs IN FOCUS: From Elon Musk and Satya Nadella to the co-founder of Moderna, it’s not just tycoons in Silicon Valley who have benefited from the controversial work visa now in Donald Trump’s crosshairs, writes Io Dodds The Independent UK · Oct 12, 2025
Moderna Stock Is Rallying Wednesday: What's Driving The Action? Moderna Inc (NASDAQ:MRNA) stock is trading higher Wednesday afternoon, lifted by positive sentiment across the pharmaceutical sector. The rally follows a landmark agreement Tuesday between Pfizer Inc (NYSE:PFE) and the Trump administration to lower prescription drug prices. Benzinga · Oct 1, 2025
Moderna Stands By UK As Pharma Giants Criticize Pricing, UK Secures First Onshore mRNA Vaccine Production Centre Moderna, Inc.‘s (NASDAQ: MRNA) UK chief Darius Hughes defended Britain's drug pricing policies after the country was branded the "worst in Europe." Benzinga · Sep 25, 2025
Moderna takes swipe at Trump as it opens new UK factory: ‘A country that still believes in vaccination’ New opening comes amid a rise in anti-vax attitudes within the Trump administration The Independent UK · Sep 25, 2025
Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility ‘We’re here to invest,’ says Darius Hughes as he calls comments by other pharma companies ‘a little harsh’ The Guardian - UK · Sep 24, 2025
The Independent UK · Sep 24, 2025 Moderna opens new vaccine facility in boost for UK pharmaceutical industry The plant in Oxfordshire can make up to 100 million doses per year.
Benzinga · Sep 24, 2025 Flagship Pioneering, Creator Of Moderna, Launches Extuitive With $20M To Reinvent Consumer Products Using AI Shoppers Flagship Pioneering, the Cambridge venture firm known for creating Moderna (NASDAQ:MRNA), last Thursday unveiled a new startup called Extuitive with $20 million in seed funding.
Benzinga · Sep 23, 2025 Moderna's COVID-19 Vaccine Update Boosts Antibodies 16-Fold, Data Shows Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2.
AAP · Sep 22, 2025 Vaccine site could save Australia billions in pandemic Australia's first sovereign mRNA vaccine facility could give the nation a shot in the arm against the next pandemic, an independent report says.
International Business Times UK · Sep 17, 2025 Moderna Shares Surge After Recording Positive Phase 4 Prelim Data on COVID-19 Drug Moderna shares rose by over 4% on a mixed Tuesday for US equities ahead of the US Federal Reserve's rate cut decision today.
Benzinga · Sep 17, 2025 What's Going On With Moderna Stock Wednesday? Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know.
Benzinga · Sep 16, 2025 Moderna Stock Is Moving Higher Tuesday: Here's Why Moderna, Inc. (NASDAQ:MRNA) shares are up nearly 5% on Tuesday after the company announced positive preliminary immunogenicity data for its 2025-2026 Spikevax formula, which targets the new LP.8.1 variant of COVID-19.
Benzinga · Sep 16, 2025 Moderna Reports 8-Fold Jump In Antibodies With Updated Spikevax Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19.
Benzinga · Sep 12, 2025 Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…
Barchart · Sep 2, 2025 Is Moderna Stock Underperforming the S&P 500? With Moderna heavily lagging behind the broader S&P 500 Index, Wall Street appears cautious about this stock.
Benzinga · Sep 1, 2025 Robert Kennedy Jr.'s Leadership Can Only Bring More 'Harm,' Says Top Ex-CDC Official: 'Undoing Of Vaccination' In Works Former Centers for Disease Control and Prevention immunizations chief Demetre Daskalakis said Sunday he resigned because politics has overrun science at the nation's top public-health agency, warning he "only see[s] harm coming" under Health and Human Services Secretary Robert F. Kennedy Jr.